BLTE Latest Press Releases

-- November 5, 2026 --

Belite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results Globe Newswire 8:00 AM

-- October 19, 2026 --

Belite Bio Announces Uplisting to the Nasdaq Global Select Market Globe Newswire 6:00 AM

-- October 14, 2026 --

Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1 Globe Newswire 4:00 PM

-- September 28, 2026 --

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences Globe Newswire 8:00 PM

-- September 8, 2026 --

Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1 Globe Newswire 6:00 AM

-- September 1, 2026 --

Belite Bio to Participate in Four Upcoming Investor Conferences Globe Newswire 8:00 AM

-- August 24, 2026 --

Belite Bio to Host Virtual Commercial Day on September 2, 2026 Globe Newswire 4:00 PM

-- August 21, 2026 --

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences Globe Newswire 8:00 AM

-- August 12, 2026 --

Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update Globe Newswire 9:45 PM

-- August 11, 2026 --

Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1 Globe Newswire 4:01 PM

-- August 6, 2026 --

Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results Globe Newswire 8:00 AM

-- July 20, 2026 --

Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1 Globe Newswire 8:00 AM

-- July 15, 2026 --

Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference Globe Newswire 8:00 AM

-- July 6, 2026 --

Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium Globe Newswire 8:00 AM

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences Globe Newswire 7:00 AM

-- June 12, 2026 --

Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Globe Newswire 9:30 PM

Market Data Delayed 15 Minutes